Tideglusib for genetic arrhythmogenic cardiomyopathy
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a medication called tideglusib to see if it can reduce extra heartbeats in people with a genetic form of arrhythmogenic cardiomyopathy. It may help stabilize the heart's rhythm and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific genetic change in a heart muscle gene (like PKP2, DSG2, or TMEM43).
- You need to have at least 500 extra heartbeats (PVCs) per day on a week-long heart monitor.
- Your diagnosis or genetic carrier status should have been known for at least 6 months.
- You cannot have severe heart failure (NYHA class IV) or liver problems.
- You should not be taking certain heart rhythm medications or strong CYP3A4 inhibitors (like some antibiotics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
This trial evaluates early prevention and treatment strategies for arrhythmogenic cardiomyopathy (ACM), a heart condition that can cause abnormal heart rhythms. It aims to improve care by using advanced tests like heart imaging and genetic sequencing to guide treatment.
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
This trial studies how safe and effective tideglusib is for children and young adults with congenital or childhood-onset myotonic dystrophy type 1 (DM1). It may help researchers learn whether the medicine improves symptoms while tracking side effects closely.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This Phase 2 study tests tideglusib to see if it helps slow or improve amyotrophic lateral sclerosis (ALS). You may be eligible if you have early-stage ALS with preserved breathing ability and certain stable treatments.
Hear when a new Arrhythmogenic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.